Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
WEDNESDAY, July 23, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk
Produkten sljs uteslutande fr forskningsndaml och r inte avsedd som lkemedel, kosttillskott eller medicinsk behandling
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis
The treatment breaks down fat cells in the injected area, and the body eliminates the released lipids
US$ 20.29
US$ 24.74
US$ 25.19
US$ 20.26
US$ 25.67
US$ 22.72
US$ 29.41
US$ 28.18
US$ 21.84
US$ 23.35
US$ 24.05
US$ 24.39
